Last modifications on European GMP, which are taking effect on Mach 15th, (Chapter 3 and especially Chapter 5) are going to impact on existing facilities and equipment, and they are going to force a rethinking of all steps and measures to be taken in order to avoid cross contamination; not just for these products so-called “high potency” but in general for all pharmaceutical products. Every pharmaceutical product must have a risk analysis based on a toxicological assessment. Measures to be taken in order to avoid cross contamination will be determined in accordance with a risk analysis, based on the Quality Risk Management principles and they should be commensurate with the risksRead more
INGELYT, through our partner QUALIA, has attended the last CHINA PHARM 2014
19th edition of CHINA-PHARM, hold in Shenzen the last October, the fair occupied more than 30.000m2 with 431 exhibitors from 22 countries.
In cooperation with QUALIA , INGELYT introduced some of its high specialized products, as the airtight doors with pneumatic seal.
In addition INGELYT introduced the new services of consultancy and advising focused to the Pharmaceutical Industry.
1. Overview Energy recovery from HVAC exhaust is an important matter on the point of view of energy efficiency. In pharmaceutical industry, biotechnology, research labs and hospitals, 100% fresh air is very common and most times mandatory. In a 100% […]Read more
In the pharmaceutical sector there is a clear tendency to develop and manufacture high potent products, currently they represent 35% of the global market share and 50% of products under development (Class 3 and 4 Safebridge classification). New areas or […]Read more